Jennifer A Sinnott

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/226035/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of circulating leukocyte telomere length with survival in patients with colorectal cancer. Journal of Geriatric Oncology, 2022, , .	1.0	3
2	More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer. American Journal of Obstetrics and Gynecology, 2022, 227, 244.e1-244.e17.	1.3	8
3	Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomes. Gynecologic Oncology, 2020, 158, 407-414.	1.4	16
4	Pathway aggregation for survival prediction via multiple kernel learning. Statistics in Medicine, 2018, 37, 2501-2515.	1.6	7
5	Kernel machine score test for pathway analysis in the presence of semi-competing risks. Statistical Methods in Medical Research, 2018, 27, 1099-1114.	1.5	2
6	Life after endometrial cancer: A systematic review of patient-reported outcomes. Gynecologic Oncology, 2018, 148, 403-413.	1.4	54
7	PheProb: probabilistic phenotyping using diagnosis codes to improve power for genetic association studies. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1359-1365.	4.4	18
8	Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency. European Urology, 2018, 74, 545-548.	1.9	5
9	Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival. Gynecologic Oncology, 2018, 150, 38-43.	1.4	9
10	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis, 2018, 39, 1431-1437.	2.8	35
11	Prognostic Utility of a New mRNA Expression Signature of Cleason Score. Clinical Cancer Research, 2017, 23, 81-87.	7.0	58
12	The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer & Metabolism, 2016, 4, 22.	5.0	26
13	Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. European Urology, 2016, 70, 974-982.	1.9	72
14	Reply to Herney Andrés GarcÃa-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974–82. European Urology, 2016, 70, e156-e157.	1.9	0
15	Inference for survival prediction under the regularized Cox model. Biostatistics, 2016, 17, 692-707.	1.5	14
16	Sniffing out significant "Pee valuesâ€; genome wide association study of asparagus anosmia. BMJ, The, 2016, 355, i6071.	6.0	11
17	Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Research, 2016, 76, 4785-4790.	0.9	61
18	Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clinical Cancer Research, 2016, 22, 765-772.	7.0	25

2

JENNIFER A SINNOTT

#	Article	IF	CITATIONS
19	Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis, 2015, 36, 632-638.	2.8	34
20	Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis, 2015, 36, 639-647.	2.8	25
21	Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Molecular Cancer Research, 2015, 13, 1431-1440.	3.4	15
22	Association of Prostate Cancer Risk Variants with Gene Expression in Normal and Tumor Tissue. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 255-260.	2.5	97
23	Cholesterol metabolism and prostate cancer-specific mortality Journal of Clinical Oncology, 2015, 33, 12-12.	1.6	1
24	Improving the power of genetic association tests with imperfect phenotype derived from electronic medical records. Human Genetics, 2014, 133, 1369-1382.	3.8	40
25	SPINK1 Protein Expression and Prostate Cancer Progression. Clinical Cancer Research, 2014, 20, 4904-4911.	7.0	71
26	Omnibus Risk Assessment via Accelerated Failure Time Kernel Machine Modeling. Biometrics, 2013, 69, 861-873.	1.4	7
27	Artifact due to differential error when cases and controls are imputed from different platforms. Human Genetics, 2012, 131, 111-119.	3.8	29